The overarching objective of Immune-Image is to develop a novel non-invasive imaging strategy for assessing immune cell activation and dynamics in oncology and inflammatory disease, in animal models and in patients. To achieve this goal, 22 organisations will be working in 7 workpackages during 5 years.
Specifically, within Immune-Image we will:
Develop an infrastructure for data sharing, harmonisation and biobanking.
Generate imaging agents for characterisation of specific immune cell subsets.
Develop and optimise imaging workflows and conduct proof-of-principle studies.
Validate immunotracers in disease models with the aim of making them applicable to clinical studies.
Conduct human clinical trials to confirm safety and to evaluate the clinical potential of novel immunotracers.
WP1. Management, coordination, dissemination and sustainability
WP1 leaders: VUMC and Roche
Partners involved: VUMC, WWU, TTOP, Lawrencium, ECPC, Roche
WP2. Data storage and analysis enablement
WP2 Leaders: Lygature and Bayer
Partners involved: VUMC, UMCG, Antaros, LYG, Lawrencium, ECPC, Bayer, Janssen, Takeda
WP3. Generation of imaging reagents to uniquely identify
specific cell types
WP3 Leaders: VUB and Roche
Partners involved: VUMC, EKUT, WWU, VUB, VIB, UMCG, Roche, Janssen, Pfizer, Takeda
WP4 Leaders: EKUT and Roche
Partners involved: VUMC, EKUT, UCAM, WWU, VUB, VIB, UMCG, VHIO, VHIR, Roche, Bayer, Janssen, Pfizer
WP5. Implementation of immunotracers for longitudinal assessment and therapy monitoring in pre-clinical disease models in vivo
WP5 Leaders: WWU and ImaginAb
Partners involved: VUMC, EKUT, UCAM, WWU, VUB, VIB, UMCG, VHIO, VHIR, CEA, Roche, Bayer, Janssen, Pfizer, ImaginAb, Takeda
WP6. Trials with immunotracers in patients with cancer and inflammatory diseases
WP6 Leaders: UMCG and Novartis
Partners involved: VUMC, EKUT, UCAM, WWU, VUB, UMCG, VHIO, VHIR, Antaros, LYG, Roche, Bayer, Janssen, Novartis, Pfizer, ImaginAb, Takeda
WP7. Ethics requirements
Partners involved: VUMC
Project acronym: Immune-Image
Full project title: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies
Grant Agreement ID: 831514
Project start date: 1 October 2019
Project end date: 30 September 2024
Project duration: 60 months
Project budget: € 27,200,801.38
EU contribution: € 15,000,000
EFPIA contribution: € 12,200,801.38
Project leads: Bert Windhorst (VUMC) and Jason Hannon (Roche)